PedAM
Pediatric Disease Annotations & Medicines
| myeloid leukemia | ||||
| Disease ID | 316 |
|---|---|
| Disease | myeloid leukemia |
| Manually Symptom | UMLS | Name(Total Manually Symptoms:6) |
| Text Mined Symptom | UMLS | Name | Sentences' Count(Total Symptoms:4) C0005699 | blast crisis | 16 C0009450 | infection | 15 C0019080 | hemorrhage | 3 C0836924 | thrombocythemia | 1 |
Manually Genotype(Total Text Mining Genotypes:0) |
|---|
| (Waiting for update.) |
All Snps(Total Genotypes:14) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| snpId | pubmedId | geneId | geneSymbol | diseaseId | sourceId | sentence | score | Year | geneSymbol_dbSNP | CHROMOSOME | POS | REF | ALT |
| rs10514611 | 24886876 | 3394 | IRF8 | umls:C0023470 | BeFree | In adult myeloid leukemias we found significant associations between the variant allele of PML_rs9479 and decreased AML risk (OR = 0.61 (0.38-0.97), and between variant alleles of IRF8_ rs10514611 and ARHGAP26_rs187729 and increased CML risk (OR = 2.4 (1.12-5.15) and 1.63 (1.07-2.47), respectively). | 0.000814326 | 2014 | IRF8 | 16 | 85921636 | C | T |
| rs10514611 | 24886876 | 5371 | PML | umls:C0023470 | BeFree | In adult myeloid leukemias we found significant associations between the variant allele of PML_rs9479 and decreased AML risk (OR = 0.61 (0.38-0.97), and between variant alleles of IRF8_ rs10514611 and ARHGAP26_rs187729 and increased CML risk (OR = 2.4 (1.12-5.15) and 1.63 (1.07-2.47), respectively). | 0.001357209 | 2014 | IRF8 | 16 | 85921636 | C | T |
| rs10514611 | 24886876 | 23092 | ARHGAP26 | umls:C0023470 | BeFree | In adult myeloid leukemias we found significant associations between the variant allele of PML_rs9479 and decreased AML risk (OR = 0.61 (0.38-0.97), and between variant alleles of IRF8_ rs10514611 and ARHGAP26_rs187729 and increased CML risk (OR = 2.4 (1.12-5.15) and 1.63 (1.07-2.47), respectively). | 0.000271442 | 2014 | IRF8 | 16 | 85921636 | C | T |
| rs187729 | 24886876 | 3394 | IRF8 | umls:C0023470 | BeFree | In adult myeloid leukemias we found significant associations between the variant allele of PML_rs9479 and decreased AML risk (OR = 0.61 (0.38-0.97), and between variant alleles of IRF8_ rs10514611 and ARHGAP26_rs187729 and increased CML risk (OR = 2.4 (1.12-5.15) and 1.63 (1.07-2.47), respectively). | 0.000814326 | 2014 | ARHGAP26 | 5 | 143226004 | C | T |
| rs187729 | 24886876 | 23092 | ARHGAP26 | umls:C0023470 | BeFree | In adult myeloid leukemias we found significant associations between the variant allele of PML_rs9479 and decreased AML risk (OR = 0.61 (0.38-0.97), and between variant alleles of IRF8_ rs10514611 and ARHGAP26_rs187729 and increased CML risk (OR = 2.4 (1.12-5.15) and 1.63 (1.07-2.47), respectively). | 0.000271442 | 2014 | ARHGAP26 | 5 | 143226004 | C | T |
| rs187729 | 24886876 | 5371 | PML | umls:C0023470 | BeFree | In adult myeloid leukemias we found significant associations between the variant allele of PML_rs9479 and decreased AML risk (OR = 0.61 (0.38-0.97), and between variant alleles of IRF8_ rs10514611 and ARHGAP26_rs187729 and increased CML risk (OR = 2.4 (1.12-5.15) and 1.63 (1.07-2.47), respectively). | 0.001357209 | 2014 | ARHGAP26 | 5 | 143226004 | C | T |
| rs35602083 | 16320249 | 2322 | FLT3 | umls:C0023470 | BeFree | D324N single-nucleotide polymorphism in the FLT3 gene is associated with higher risk of myeloid leukemias. | 0.056970589 | 2006 | FLT3 | 13 | 28049450 | C | T |
| rs386626619 | 19254349 | 3717 | JAK2 | umls:C0023470 | BeFree | The association of V617F JAK2 expression levels with disease behavior has not been studied in patients with nonchronic myelogenous leukemia (CML) myeloproliferative disease (MPD). | 0.01801231 | 2010 | NA | NA | NA | NA | NA |
| rs386626619 | 22579713 | 3717 | JAK2 | umls:C0023470 | BeFree | GVS inhibited colony formation and proliferation and induced apoptosis at doses two- to threefold lower in a panel of JAK2(V617F) MPN compared to JAK2 wild-type myeloid leukemia cell lines. | 0.01801231 | 2012 | NA | NA | NA | NA | NA |
| rs77375493 | 19254349 | 3717 | JAK2 | umls:C0023470 | BeFree | The association of V617F JAK2 expression levels with disease behavior has not been studied in patients with nonchronic myelogenous leukemia (CML) myeloproliferative disease (MPD). | 0.01801231 | 2010 | JAK2;INSL6 | 9 | 5073770 | G | A,T |
| rs77375493 | 22579713 | 3717 | JAK2 | umls:C0023470 | BeFree | GVS inhibited colony formation and proliferation and induced apoptosis at doses two- to threefold lower in a panel of JAK2(V617F) MPN compared to JAK2 wild-type myeloid leukemia cell lines. | 0.01801231 | 2012 | JAK2;INSL6 | 9 | 5073770 | G | A,T |
| rs9479 | 24886876 | 23092 | ARHGAP26 | umls:C0023470 | BeFree | In adult myeloid leukemias we found significant associations between the variant allele of PML_rs9479 and decreased AML risk (OR = 0.61 (0.38-0.97), and between variant alleles of IRF8_ rs10514611 and ARHGAP26_rs187729 and increased CML risk (OR = 2.4 (1.12-5.15) and 1.63 (1.07-2.47), respectively). | 0.000271442 | 2014 | PML | 15 | 74036235 | A | G |
| rs9479 | 24886876 | 3394 | IRF8 | umls:C0023470 | BeFree | In adult myeloid leukemias we found significant associations between the variant allele of PML_rs9479 and decreased AML risk (OR = 0.61 (0.38-0.97), and between variant alleles of IRF8_ rs10514611 and ARHGAP26_rs187729 and increased CML risk (OR = 2.4 (1.12-5.15) and 1.63 (1.07-2.47), respectively). | 0.000814326 | 2014 | PML | 15 | 74036235 | A | G |
| rs9479 | 24886876 | 5371 | PML | umls:C0023470 | BeFree | In adult myeloid leukemias we found significant associations between the variant allele of PML_rs9479 and decreased AML risk (OR = 0.61 (0.38-0.97), and between variant alleles of IRF8_ rs10514611 and ARHGAP26_rs187729 and increased CML risk (OR = 2.4 (1.12-5.15) and 1.63 (1.07-2.47), respectively). | 0.001357209 | 2014 | PML | 15 | 74036235 | A | G |
GWASdb Annotation(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
GWASdb Snp Trait(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
Mapped by lexical matching(Total Items:0) |
|---|
| (Waiting for update.) |
Mapped by homologous gene(Total Items:0) |
|---|
| (Waiting for update.) |
Chemical(Total Drugs:16) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| CUI | ChemicalName | ChemicalID | CasRN | DiseaseName | DiseaseID | DirectEvidence | PubMedIDs | ||
| C0023470 | arsenic trioxide | C006632 | 1327-53-3 | leukemia, myeloid | MESH:D007951 | therapeutic | 19077051 | ||
| C0023470 | azacitidine | D001374 | 320-67-2 | leukemia, myeloid | MESH:D007951 | therapeutic | 19077051 | ||
| C0023470 | busulfan | D002066 | 55-98-1 | leukemia, myeloid | MESH:D007951 | therapeutic | 2332518 | ||
| C0023470 | chloramphenicol | D002701 | 56-75-7 | leukemia, myeloid | MESH:D007951 | marker/mechanism | 6071896 | ||
| C0023470 | cladribine | D017338 | 4291-63-8 | leukemia, myeloid | MESH:D007951 | therapeutic | 9498718 | ||
| C0023470 | dasatinib | D000069439 | - | leukemia, myeloid | MESH:D007951 | therapeutic | 26008977 | ||
| C0023470 | decitabine | C014347 | 2353-33-5 | leukemia, myeloid | MESH:D007951 | therapeutic | 17236224 | ||
| C0023470 | hydroxyurea | D006918 | 127-07-1 | leukemia, myeloid | MESH:D007951 | marker/mechanism | 16532439 | ||
| C0023470 | hydroxyurea | D006918 | 127-07-1 | leukemia, myeloid | MESH:D007951 | therapeutic | 2332518 | ||
| C0023470 | imatinib mesylate | D000068877 | - | leukemia, myeloid | MESH:D007951 | therapeutic | 17236224 | ||
| C0023470 | ponatinib | C545373 | - | leukemia, myeloid | MESH:D007951 | therapeutic | 26008977 | ||
| C0023470 | thiotepa | D013852 | 52-24-4 | leukemia, myeloid | MESH:D007951 | marker/mechanism | 10069464 | ||
| C0023470 | tretinoin | D014212 | 302-79-4 | leukemia, myeloid | MESH:D007951 | marker/mechanism | 19285840 | ||
| C0023470 | tretinoin | D014212 | 302-79-4 | leukemia, myeloid | MESH:D007951 | therapeutic | 16482212 | ||
| C0023470 | vincristine | D014750 | - | leukemia, myeloid | MESH:D007951 | therapeutic | 4348690 | ||
| C0023470 | vindesine | D014751 | 53643-48-4 | leukemia, myeloid | MESH:D007951 | therapeutic | 3469429 | ||
FDA approved drug and dosage information(Total Drugs:0) | |
|---|---|
| (Waiting for update.) | |
FDA labeling changes(Total Drugs:0) | |
|---|---|
| (Waiting for update.) | |